Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

OBJECTIVES: Immune checkpoint inhibitors have emerged as novel treatment options in patients with endometrial cancer. In this study we aimed to compare the survival outcomes of patients with recurrent or advanced endometrial cancer. These patients had received dostarlimab after platinum-based chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulden, Scott, Heffernan, Kiera, Sen Nikitas, Fulya, Shukla, Urmi, Knott, Craig, Hunger, Matthias, Pahwa, Ankit, Schade, Rene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646891/
https://www.ncbi.nlm.nih.gov/pubmed/37620100
http://dx.doi.org/10.1136/ijgc-2022-004178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646891/
https://www.ncbi.nlm.nih.gov/pubmed/37620100
http://dx.doi.org/10.1136/ijgc-2022-004178

Ejemplares similares